AKT1 and breast cancer: Although our study revealed that mutated PI3K-AKT pathway could potentially indicate the lack of response to EC-T(H) regimen, further prospective studies or clinical trials should be launched to investigate how to personalize optimal treatment to BC patients with NAC resistance, according to patients’ receptor status and genomic profiles.